Novel selective CYP11B1 Inhibitors
Scientists of Saarland University have recently succeeded in developing the first CYP11B1 inhibitors showing good selectivity. As starting point the highly active CYP11B1 inhibitor Etomidate has been used. Via several modifications followed by further optimizations realized at this molecule, it was possible to increase the selectivity resulting in a very weak inhibition towards CYP11B2 and no inhibition of CYP17 and CYP19.
Further Information: PDF
Universität des Saarlandes Wissens- und Technologietransfer GmbH PatentVerwertungsAgentur der saarländischen Hochschulen
Phone: +49 (0)681/302-71302
Contact
Dipl.-Kfm. Axel Koch (MBA), Dr. Conny Clausen, Dr. Hauke Studier, Dr. Susanne Heiligenstein
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Security vulnerability in browser interface
… allows computer access via graphics card. Researchers at Graz University of Technology were successful with three different side-channel attacks on graphics cards via the WebGPU browser interface. The attacks…
A closer look at mechanochemistry
Ferdi Schüth and his team at the Max Planck Institut für Kohlenforschung in Mülheim/Germany have been studying the phenomena of mechanochemistry for several years. But what actually happens at the…
Severe Vulnerabilities Discovered in Software to Protect Internet Routing
A research team from the National Research Center for Applied Cybersecurity ATHENE led by Prof. Dr. Haya Schulmann has uncovered 18 vulnerabilities in crucial software components of Resource Public Key…
